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This study reviews the case of an adolescent male experiencing mood and psychotic symptoms 
with concurrent illicit Adderall use.  Risk factors for developing adverse effects from 
psychostimulants are reviewed in the literature.  Risks of developing mania and psychosis 
following administration of therapeutic doses of psychostimulants were found to be less than 1%.  
The likelihood of developing psychosis is far greater when high doses of stimulants are being 
used as illustrated in the case study.  Research demonstrated that the majority of these symptoms 
subside or disappear completely when stimulant use ceases.  Benefits of therapeutic doses of 
psychostimulants in the treatment of attention deficit and hyperactivity disorders (ADHD) are 
discussed.  Complications can result when individuals are experiencing symptoms of ADHD as 
well as thought and mood disorders.  Clinicians need to ensure schizophrenia and bipolar 
disorders are treated first as the initiation of psychostimulants can exacerbate manic and 
psychotic symptoms in this population.  This was demonstrated throughout the literature review.  
Psychostimulants should be used cautiously in children and adolescents with a family history of 
bipolar and schizophrenia.  Literature indicates that psychostimulants can hasten mood and 
psychotic symptoms in adolescents that already have a genetic predisposition to these mental 
health conditions.       
Background 
As America is in the midst of an opiate epidemic, the stimulant crisis appears to be 
lurking in the shadows.  According to the National Institute of Health and Care Excellence, 
prescriptions for Ritalin and medications similar to it, have doubled in the past decade (2015). 
The CDC reported that overdose deaths that occurred as a result of psychostimulant abuse rose 
30% from the year 2016 to 2017 (www.cdc.gov).  
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 Although psychostimulants remain the first line pharmacotherapy for the treatment of 
ADHD, they are not without risks.  Prescriptions for this classification of medications should be 
written judiciously.  Abuse potential is high and although rare, adverse effects such as psychosis 
and mania, can occur.  This paper will further explore the correlation between the use of 
psychostimulants and the development of psychotic symptoms.  
Case Report 
 It was a warm, September day when a 17 year-old male patient, A.S., presented to the 
mental health clinic for his appointment.  He walked in wearing a heavy winter coat with a 
disheveled appearance.  His chief complaint was severe anxiety and ongoing depression.  A.S. 
had begun taking Seroquel 50mg nightly within the past 6 months.  This was prescribed by his 
previous provider, and he denied a history of other medication trials.  A.S. reported no history of 
inpatient psychiatric hospitalizations but admitted to feeling depressed for many years.  He 
denied current thoughts or previous attempts of suicide.  Socially, the patient was in his final 
year of high school, but he opted to take online classes because he stated, “I can’t stand being 
around people.”  He lived with his mother and father, but reported he didn’t interact with them 
much as he spent most of his time in the garage.  A.S. reported working full-time in food service. 
When questioned about being around people, he clarified, “I don’t mind being around people 
when money is involved.”  In the session, A.S. was observed to be hypervigilant with darting eye 
contact.  He described unusual sleep and appetite patterns such as being up for days and then 
sleeping for days.  At times, he would restrict his food intake by going 3-4 days without eating, 
and then followed this with binging episodes.  A.S. was positive for both auditory and visual 
hallucinations; he reported a time where he saw people in his front yard.  “My parents got 
concerned for me,” he explained.  A.S. has heard chatter or noise in the past as well.  “But then I 
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look around the house, and no one else is there,” he explained.  He also expressed some bizarre 
and paranoid thought content throughout the course of the interview.  The patient reported never 
eating the food from his work because “those burgers are not made of beef”.  “What do you think 
they do with all the refugees that come to Minnesota from other countries?” insinuating the food 
at the restaurant came from human remains.  A.S. engaged in high-risk behaviors such as stealing 
and selling and buying illicit substances.  Again, he reiterated the fact that he doesn’t like being 
around people, but “these guys are my dealers,” he explained.  A.S. has bought Adderall off the 
street for “the past couple years”.  He reported taking 30mg in the morning, and an additional 
20mg at dinner time on the nights he works late and closes the restaurant.  A.S. stated the 
Adderall helps him feel less depressed and keeps him alert.  He denied any history of ADHD. 
The patient reported he has one brother, who is in treatment for methamphetamine addiction. 
Other than this, he denied any other family history of mental illness or substance abuse. 
 This patient showed evidence of both a mood and thought disorder.  It was difficult to 
ascertain if these symptoms were a direct result of the Adderall, or if the Adderall had simply 
precipitated his psychotic and manic symptoms.  A.S. displayed poor insight and judgment, and 
it appeared unlikely that he will stop using illicit substances.  Due to this, it is difficult to get a 
baseline of what A.S. would be like when he’s not abusing substances.  A working diagnosis of 
substance-induced mood disorder was established.  Schizoaffective disorder, major depressive 
disorder with psychotic features, and schizotypal personality disorder are differential diagnoses 
to consider.  Laboratory tests which included a CBC, CMP, TSH, and Vit D levels were ordered 
in addition to a urine drug screen.  Education was provided on the dangers of Adderall use, and 
the fact that it was likely contributing to the high levels of anxiety he’s experiencing.  Seroquel 
was increased to 100mg nightly in an effort to reduce anxiety, depression, hallucinations, and 
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regulate mood and sleep patterns.  A.S. was expected to return back to the clinic in 4 weeks for 
follow-up.  Our short-term goals included continuing to build rapport with the patient and 
allowing a trusting relationship to grow.  Although he was unwilling to stop illicit Adderall use 
at the time of the appointment, this will need to be assessed at each prospective visit.  It’s 
unlikely a remission in either his psychotic or manic symptoms will occur if this change does not 
take place. 
Literature Review 
 The above case report prompted a thorough research investigation between the use of 
psychostimulants and the onset of psychosis.  The databases PubMed, PsycInfo, and CINAHL 
were utilized.  The search terms “psychostimulants” AND “psychosis” were entered.  Filters 
included full-text articles and those published within the past 10 years.  PubMed yielded 110 
results whereas PsycInfo and CINAHL yielded 131 and 13 research articles respectively.  Titles 
and abstracts were reviewed.  Eventually, 12 articles were selected that were found to be the 
most relevant for the chosen topic. 
 Prior to sharing research that discusses adverse effects from psychostimulant use, it is 
remarkable to report there has been an extensive amount of research performed on the benefits of 
psychostimulants.  A 2017 research article discusses the sensitization hypothesis.  Animal studies 
indicate that treatment with amphetamines result in a sensitizing effect.  Translating this to 
humans, the concern is that stimulants could then make the rewarding effects of other drugs more 
prominent.  However, the author found the opposite to be true.  Individuals with ADHD, being 
treated with psychostimulants, were 35% less likely to abuse substances compared to those not 
being treated with stimulants.  Children with ADHD, who received early detection and stimulant 
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treatment, were less likely to engage in impulsive, risk-taking behaviors.  Risks for developing 
co-occurring substance use disorders as adults also decreased (Asherson, 2017). 
 Despite the varied benefits of psychostimulants in not only the treatment of ADHD, but 
also narcolepsy and obesity, risk factors need to be taken into account.  To begin, it is important 
to discuss the action psychostimulants have on the brain.  Stimulant medications work by 
blocking dopamine reuptake transporters leading to an increased concentration of dopamine in 
the synapse (Ashton, Gallagher, & Moore, 2006).  
 With increased concentrations of dopamine available to bind to cell receptors, the 
 possibility of developing psychosis or mania presents itself.  Psychosis from psychostimulant  
usage was first described by Connell in 1958.  He followed a series of patients that abused  
amphetamines over a several year period (Martinez-Aquayo, Arancibia, Meza-Concha, 
Bustamante, Perez-Bracchiglione, & Madrid, 2017).  In 2007, the Federal Drug 
 Administration (FDA) issued a warning that psychostimulants being used in the treatment of  
ADHD can cause hallucinations and delusions (Karatekin, White, & Bingham, 2010).   
Angelucci, Ricci, Spalleta, Caltagirone, and Mathe (2009) hypothesized the reason for the  
psychotic symptoms involved the class of proteins known as neurotrophins.  Neurotrophins act  
on dopaminergic neurons that are affected by psychostimulants.  Psychostimulants can interfere 
with these proteins, and the neurotrophins become altered.  Since altered neurotrophins are 
believed to contribute to the development of psychiatric disorders, the authors hypothesize that 
psychostimulants can cause psychosis through this same mechanism (Angelucci et al., 2009).  
 The following research studies will emphasize the importance of dosing stimulants at 
therapeutic levels in an effort to minimize psychotic symptoms.  Cheng et al. (2014) performed 
an animal study using both high and low doses of methylphenidate.  In humans, low doses of 
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methylphenidate can have cognitive-enhancing effects such as improvement in memory and 
attention.  To the contrary, high doses can have psychosis-inducing effects and can produce 
agitation, restlessness, and hallucinations.  Cheng and colleagues studied behavioral patterns in 
rats.  Rodents dosed with low-dose methylphenidate showed an improvement in memory 
recognition tasks whereas rodents dosed with high amounts exhibited hyperlocomotion and an 
inability to complete tasks.  The researchers hypothesize the high doses of methylphenidate 
reduce glutamate signals and contribute to hyperactivity.  Whereas the low doses are thought to 
enhance cognition through intensifying the signals of N-methyl-D-aspartate receptors (Cheng et 
al., 2014).  
 Vorspan, Warot, Consoli, Cohen, and Mazet (2005) present a case that demonstrates the 
dangers of high dosing of methylphenidate on a human subject.  The researchers examine a 17 
year-old male that was placed on modafinil 400mg daily for narcolepsy.  Due to poor sleep 
patterns, a year later, he transitioned to methylphenidate 40mg daily.  Following initiation of this, 
he developed manic symptoms such as irritability, flights of ideas, and hypersexual behaviors. 
When the patient was taken off stimulants all together, he became withdrawn and anhedonic. 
Modafinil was re-introduced and a full manic episode ensued which resulted in hospitalization. 
The patient experienced visual and auditory hallucinations, insomnia, tachypsychia, and 
logorrhea (Vorspan et al., 2005).  Ashton, Gallagher, and Moore discuss common withdrawal 
effects from discontinuing stimulant use.  Depression and anhedonia, similar to what this 
adolescent patient experienced, are common.  Antidepressant medications can serve as an aide to 
alleviate such symptoms (Ashton, Gallagher, & Moore, 2006).  
 Martinez-Aguayo and colleagues examine yet another case where improper dosing of 
methylphenidate led to psychotic symptoms for a 9 year-old boy.  This patient had a diagnosis of 
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ADHD and was ordered to begin methylphenidate 5mg twice daily for one week with a target 
dose of reaching 10mg twice daily.  However, he inadvertently started at 10mg twice daily. 
While at school, the psychologist noted he displayed paranoia and was confused and 
hypervigilant.  He reported seeing and hearing goblins and dolls.  A couple hours later, he 
described himself as being scared, and couldn’t tell whether these perceptions were real or 
imagined.  His symptoms resolved the following day as the medication wore off. 
Methylphenidate was stopped and re-started two weeks later at a fraction of the dose he was 
previously on.  After 6 months, no further psychotic symptoms resurfaced.  This therapeutic 
strategy of suspending the drug and then gradually re-introducing it was effective for this young 
patient; the researchers recommend this approach (Martinez-Aguayo et al., 2017). 
 The above scenarios prompted further investigation into the probability of psychotic and 
manic symptoms developing from the use of psychostimulants.  Mosholder, Gelperin, Hammad, 
Phelan, and Johann-Liang (2009) analyzed data from 49 different randomized, controlled trials in 
pediatric patients.  Medications included in the study consisted of stimulants from the 
amphetamine and methylphenidate classes as well as Strattera and Provigil.  A total of 11 
adverse events of mania or psychosis occurred during the 743 person-years study.  Common 
patterns of hallucinations observed in children involved visual or tactile sensations of insects, 
snakes, and worms.  Follow-up reports were reviewed as well.  Findings revealed that the vast 
majority of psychotic and manic symptoms ceased shortly after the stimulant medication was 
discontinued.  The authors report that hallucinosis will occur in approximately 0.25% of 
pediatric patients treated with stimulants (Mosholder et al., 2009).  This statistic is congruent 
with the Martinez-Aguayo et al. study that reports 1 in 400 patients treated with 
psychostimulants will develop psychosis.  Most often, these symptoms will surface as treatment 
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is initiated.  However, in rare occurrences, psychotic and manic symptoms can emerge several 
months into the medication therapy (Martinez-Aguayo et al., 2017). 
 Effectively treating ADHD with psychostimulants can become more complicated when 
co-occurring psychiatric disorders are present.  Martinez-Aguayo and colleagues estimate that 
patients with ADHD are 4.3 times more likely to develop schizophrenia than the general 
population.  They further explain that genetic factors associated with stimulant-induced 
psychosis overlap with those seen in schizophrenia.  Approximately, 8% of patients experiencing 
hallucinations secondary to the use of methylphenidate were later diagnosed with bipolar or 
schizophrenic disorders.  The appearance of schizophrenia can be facilitated by stimulant 
medications in those individuals with a family history of mental illness (Martinez-Aguayo et al., 
2017).  Prescribers are often reluctant to treat ADHD in patients that are also experiencing 
psychosis fearing stimulants will further exacerbate their symptoms.  However, following 
stabilization with antipsychotics, researchers address the importance of treating ADHD 
symptoms in a 2015 journal article.  Levy, Traicu, Iyer, Ashok, and Joober (2015) find that 
individuals with untreated ADHD are more prone to drug abuse.  Drug abuse in turn would 
further aggravate psychotic symptoms and result in de-stabilization (Levy et al., 2015). 
 Goldsmith, Singh, and Chang (2011) discuss another common psychiatric co-morbidity 
of ADHD, bipolar disorder.  Their findings indicate that nearly 85% of youth with bipolar 
disorder also meet diagnostic criteria for ADHD.  Much like psychotic disorders, mood disorders 
should be given treatment priority in relation to ADHD.  However, the authors explain that 
psychostimulants can be added to the treatment plan once mood stabilization has occurred.  Their 
study found that 90% of patients receiving a mood stabilizer to treat bipolar and a stimulant to 
treat ADHD remained euthymic.  Whereas between 2.5 and 10% individuals diagnosed with 
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both disorders, destabilized following the addition of a psychostimulant.  Mania, hypomania, and 
suicidality were the most common adverse effects to occur (Goldsmith, Singh, & Chang, 2011). 
 With the alarming rates of individuals experiencing ADHD and other co-morbid 
psychiatric conditions, researchers have studied what impact, if any, psychostimulants have had 
on this.  Research findings were inconsistent. Karatekin, White, and Bingham (2010) conducted 
a study on 42 participants with psychosis.  The results revealed that individuals exposed to 
psychostimulants during their childhood had a younger age of onset of psychotic symptoms than 
those not treated with stimulants.  The mean age was 11.2 years in the stimulant exposure group 
in contrast to 13.7 years in the comparison group.  Questions arise from these findings.  Were 
these differences caused by harmful effects of psychostimulants, or was it simply a variation of 
symptom severity between the two groups studied?  Other information revealed in this study was 
the significant percentage of individuals with adolescent-onset psychosis that had been 
prescribed psychostimulants, 59%.  Other studies reported this correlation to be as high as 77% 
(Karatekin, White, & Bingham, 2010). 
 Goldsmith, Singh, and Chang (2011) research implications for stimulant use and bipolar. 
Similar to findings from Karatekin and colleagues, a study of adults with bipolar exposed to 
stimulants in childhood reported an earlier onset of manic symptoms.  The average age of onset 
was 11.3 years compared to 15.6 years of those individuals not treated with stimulants.  DelBello 
and colleagues theorized that adolescents exposed to stimulants resulted in increased 
dopaminergic activity in the brain and may have primed the pathophysiology of mania. 
However, these results are in contrast to the authors’ findings.  Goldsmith, Singh, and Chang 
found that stimulants either did no harm or improved symptoms of mania in patients with bipolar 
(2011).  They found no evidence that stimulants accelerate illness and precipitate mania.  The 
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researchers conclude by saying risks for developing mania and psychosis secondary to stimulants 
are small.  Emphasis is placed on using stimulants to treat ADHD in children, so normal 
neuronal development and psychosocial functioning can occur.  This, in theory, would lead to 
healthier brain development and therefore decrease propensity towards bipolar disorder 
(Goldsmith, Singh, & Chang, 2011). 
 The above literature reviewed indicates that the risks of developing mania and psychosis 
following therapeutic doses of stimulants are quite low.  And if adverse psychiatric symptoms 
did develop, there was likely an underlying cause.  However, research done by Baker and Dawe 
(2005) on individuals abusing high dosages of amphetamines presents a far grimmer picture. The 
authors find that repeated amphetamine-induced psychotic episodes lead to the concept of 
reverse tolerance.  This process causes users to have additional psychotic episodes even if lower 
doses of amphetamines are used in the future.  Of methamphetamine abusers admitted to the 
hospital in this study, approximately half had been diagnosed with a psychotic illness.  This was 
after amphetamine use had commenced.  It’s often difficult to distinguish between drug-induced 
psychosis or pre-existing psychosis precipitated by amphetamine use.  While the majority of 
psychotic symptoms brought on by amphetamine binges will resolve within days of drug 
cessation, this doesn’t happen all of the time.  To add further intricacies, some individuals will 
have drug-induced psychotic symptoms that persist throughout the course of their hospitalization 
and last over a month.  One final complication noted by the researchers is the fact that many 
patients will relapse following discharge from the hospital (Baker & Dawe, 2005).  For the 
reasons stated above, a clear diagnostic picture is difficult to obtain.  This leads back to the case 
study presented at the beginning of the paper.  It is probable the young adolescent patient 
described has a primary mental health condition, but this is challenging to decipher with his 
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ongoing amphetamine abuse.  The amphetamines are likely exacerbating what was already a pre-
existing vulnerability.  
 Current research focuses on reducing the abuse potential and psychotic symptoms 
occurring with psychostimulant usage.  An article by Darakhshan (2013) concentrates on 5-
hydroxytryptamine (5-HT).  The 5-HT receptor is known to be involved in psychotic symptoms 
associated with schizophrenia and also plays a role in the rewarding effects of drug abuse.  Since 
5-HT-1A receptors are elevated in the brains of patients with schizophrenia, the author focuses 
on this same receptor in regards to psychostimulant use.  Amphetamine sensitization is discussed 
throughout the article and is thought to underlie the reason addicts experience severe cravings.  It 
was suggested that serotonin, not dopamine, was involved in causing and maintaining this 
sensitization to stimulants.  Long-term use of amphetamines is believed to produce changes in 5-
HT-1A receptors.  Their functions then become disrupted.  However, co-administration of 5-HT-
1A agonists with stimulants can prevent this change from occurring (Darakhshan, 2013). 
Although additional work remains, preclinical research looks promising. 
Implications 
 Health care providers need to be mindful of the resulting psychosis and mania that can 
occur after prescribing a psychostimulant.  These symptoms can be minimized by starting 
patients on low doses of stimulant medications and titrating up slowly.  Special precautions 
should be used in prescribing stimulants to patients that have a genetic predisposition to 
schizophrenia or bipolar.  Although, no research was found to indicate that stimulants contribute 
to the development of such conditions, current literature suggests symptoms of schizophrenia 
and bipolar occur at younger ages when patients were exposed to stimulant medications during 
childhood.  Lastly, psychostimulants have many benefits for individuals with ADHD, and this 
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research was not intended to deter their use.  However, providers must continue to utilize sound 
judgment and weigh the benefits versus risks ratios prior to prescribing this class of medications. 
Extended release formulations can be used to minimize abuse potential.  Additional research 
needs to be performed on psychosis related to psychostimulant use to promote further 
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